loading page

Exosomes of immune cell origin and their Therapeutic potential for tumors
  • +4
  • Hongru Ai,
  • Xinya Zheng,
  • Guangyao Li,
  • Yitan Zou,
  • Lei Changhai,
  • Fu Wenyan,
  • Shi Hu
Hongru Ai
University of Shanghai for Science and Technology
Author Profile
Xinya Zheng
University of Shanghai for Science and Technology
Author Profile
Guangyao Li
Second Military Medical University
Author Profile
Yitan Zou
Second Military Medical University
Author Profile
Lei Changhai
Second Military Medical University
Author Profile
Fu Wenyan
Second Military Medical University

Corresponding Author:fuwenyan@fengmed.com

Author Profile
Shi Hu
The Second Military Medical University
Author Profile

Abstract

Exosomes are nanoscale membrane vesicles identified by electron microscopy in 1946. They are approximately 30-150 nanometers in size. Originally, exosomes were thought to be used to eliminate excess components from cells to maintain their normal physiology. In recent years, studies have shown that the function and targeting of specific cellular components in exosomes have important implications for the regulation of cellular communication. In the last few years, exosomes have been implicated in oncology, infections and other diseases and have been shown to have an impact on cancer progression. New advances in cancer immunotherapy have occurred as a result of the identification of Exosomes of immune cell origin, expanding the existing anti-cancer immune response. This paper details exosomes derived from dendritic cells, T-lymphocytes (CD4+ T-cells, CD8+ T-cells, CAR-T-cells), natural killer cells and their promising applications in tumor therapy.
14 Apr 2024Submitted to View
08 May 2024Review(s) Completed, Editorial Evaluation Pending
08 May 2024Submission Checks Completed
08 May 2024Assigned to Editor
16 May 2024Reviewer(s) Assigned
17 Jun 20241st Revision Received
17 Jun 2024Submission Checks Completed
17 Jun 2024Assigned to Editor
17 Jun 2024Review(s) Completed, Editorial Evaluation Pending
18 Jul 2024Editorial Decision: Accept